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culminating in organ failure and death. Fibrosis, believed to result from
a hyperactive tissue repair programme, is characterized by the
abnormal presence of the myofibroblast, a specialized type of
fibroblast that overexpresses the highly contractile protein a-smooth
muscle actin, which displays excessive adhesive properties. The
precise contribution of adhesive signalling, which involves integrin-
mediated activation of focal adhesion kinase (FAK)/src, to the fibrotic
phenotype of cutaneous SSc fibroblasts is unclear.
Methods. Fibroblasts (n¼6) and skin biopsies were obtained from
control and SSc tissue, and derived from mouse embryonic and
mouse integrin b1 wild-type and knockout. Proteins and RNAs
including phospho-FAK, FAK, CCN2, vinculin, a-SMA and Type I
collagen antibodies were examined by IF staining, RT–PCR and
western blot analysis. Cells were incubated for 24 h in the presence
or absence of anti-integrin b1 antibody, N-acetyl cysteine (NAC)
or PP2 (10mM). In addition, the ability matrix remodelling in
collagen contraction models and migration assays were also
examined.
Results. Histological analysis of SSc dermal tissues reveals
differential expression of p-FAK protein compared with control
dermis. FAK phosphorylation was found to be reduced in integrin b1
knockout mouse dermal fibroblasts. Neutralizing anti-integrin b1
antibody or the anti-oxidant NAC reduces FAK phosphorylation
in SSc fibroblasts. These results show integrin b1 and reactive
oxygen species (ROS) are required for the elevated FAK phosphoryla-
tion in SSc fibroblasts. The FAK/src inhibitor PP2 significantly
decreases expression of pro-fibrotic mRNAs and proteins in normal
and SSc dermal fibroblasts, such as CCN2, a-SMA and Type I
collagen (P<0.05). When normal and SSc fibroblasts were subjected
to the floating collagen gel model of ECM contraction and the
scratch wound assay of cell migration, in the presence or absence of
PP2 and anti-integrin b1 antibody, both of them reduced the enhanced
ability of SSc fibroblasts to contract a collagen gel matrix and
migration.
Conclusion. These results suggest that the excessive adhesion of SSc
fibroblasts to ECM is intimately involved with the fibrotic phenotype
of this cell type; blocking adhesive signalling may be beneficial in
controlling fibrosis.
S.10.4 OVEREXPRESSION OF IL-6 IN EARLY dcSSc MAY
DRIVE FIBROTIC RESPONSE VIA JAK2/STAT3 SIGNALLING
PATHWAYS
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Introduction. Previously we showed that a subset of dcSSc with
elevated serum IL-6 levels were associated with high modified Rodnan
skin score (mRSS). In this study, we examined its potential pro-fibrotic
effects and downstream signalling pathways in patients with early
dcSSc.
Methods. Using skin biopsies obtained from patients with early dcSSc
[n¼ 10, mean disease duration, mean (S.E.M.) 35 (9.5) months] and
healthy controls (n¼5), colocalization of IL-6 with aSMA and phospho-
STAT3 were determined immunohistochemically. The effect of IL-6
trans-signalling on extracellular matrix (ECM) production was
assessed on fibroblasts grown by explant culture from skin of SSc
patients and healthy controls. Downstream signalling pathways
regulated by IL-6 and soluble IL-6 receptor was examined using
pharmacological inhibitors. These were stimulated overnight with IL-6
(0–50 ng/ml) and sIL-6R (20 ng/ml).
Results. There was increased dermal IL-6 expression in patients with
early dcSSc compared with healthy controls. IL-6 accumulation
was strongly associated with vascular structures and perivascular
inflammatory infiltrate in 8/10 patients. Compared with controls,
immunostaining for downstream IL-6 signalling molecules showed
an increased expression of pSTAT3 in all cases with early dSSc,
particularly in the perivascular inflammatory foci and vascular
structures. Similar colocalization of IL-6 and aSMA was observed in
all skin sections with early dcSSc.
To explore the effect of IL-6 trans-signalling on ECM synthesis,
incubation of dermal fibroblasts from healthy controls with either IL-6
alone (25–50 ng/ml) or sIL-6R (20 -ng/ml) alone had no effect on
collagen, aSMA and CTGF production. However, there was up-
regulation of collagen synthesis in normal fibroblasts [34.3 (2.45) vs
9.88 (1.54) Densitometry Image Unit (DIU) controls, P<0.05] in
response to IL-6 and sIL-6R. Similar induction of aSMA and CTGF
by 12-fold and 15-fold (P< 0.01), respectively, were observed in
normal fibroblasts incubated with a combination of IL-6 and sIL-6R.
The IL-6 trans-signalling activation of collagen synthesis in normal
fibroblasts was abrogated by AG490 (3.6-fold) and S3I-201 (3.5-fold,
P<0.02), that targets JAK2 and STAT3 signalling pathways,
respectively.
Time-course analysis indicates that IL-6 trans-signalling induces
maximal activation of pJAK2 and pSTAT3 at 45 min and this was
diminished by 2 h in normal fibroblasts. Constitutive activation of both
JAK2 and STAT3 pathways was observed in SSc fibroblasts.
Conclusion. Our results confirm overexpression of IL-6 in dcSSc and
demonstrate a potent pro-fibrotic effect of IL-6 trans-signalling via
the JAK2/STAT3 pathways. The data supports the rationale targeting
the IL-6 trans-signalling as a potential fibrotic therapy in SSc.
SESSION 11
THE HAND
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Objective. We previously showed that DU significantly increased
global and hand disability with a significant impact on activities of daily
living (ADLs) and work disability. This study aims to evaluate the
impact of digital ulcer (DU) healing on disability and daily activity
limitations in SSc.
Methods. From January 2008 and June 2009, we prospectively
evaluated 189 SSc patients for DU history, disability, employment and
occupational status during meetings of the French SSc Patient
Association (n¼86, 45.5%) or during hospitalization (n¼ 103,
54.5%)1. Among the 60 patients with at least one active DU at
baseline (M0), 40 patients were followed longitudinally over 6 (3)
months. These patients were evaluated for DU history, global and
hand disability, health-related quality of life (HRQoL), daily activity
limitation and employment status.
Results. The median (IQR) age was 57.5 (43.5–68) years and the
median (IQR) disease duration was 8.3 (3–16.5) years. Twenty-two
(55%) patients had diffuse SSc and 34 (85%) were females.
At baseline, a mean of 2.9 (2.8) DU per patient was reported. Thirty-
three (82.5%) patients had ischaemic DU, 7 (17.5%) patients had >1
DU associated with calcinosis and 13 (32.5%) patients had mechanical
DU. Thirteen (32.5%) patients had >4 DU at baseline. Among the 40
patients, 16 (40%) patients showed complete ulcer healing. In these
patients with DU, the presence of calcinosis was associated with a
lower probability of healing (P¼ 0.03). Comparison between healed
and no-healed DU patients showed an improvement of hand disability
provided by an improvement of the Cochin Hand Function score
(P¼0.05)) and a trend towards HAQ domain dressing and grooming
(P¼0.06) between M0 and M6 (3) visit in healed patients but not in no-
healed patients. Concerning HRQoL, there were no difference for
Mental and Physical component Scores of SF-36 but significant
improvement of Bodily Pain score (P¼0.04) and Physical Role score
(P¼0.05) between M0 and M6 (3) visit in patients with healed DU. The
absence of healing was associated with significantly decreased work
productivity (P¼0.05), whereas the performance in ADL was not
significantly decreased (P¼0.15). Patients who were on sick-leave
and who received some help for household tasks at the time of active
DU were more likely to heal.
Conclusion. For the first time, we provide prospective data
with evidence that DU healing is associated with an improve-
ment in hand function. Sick leave was associated with better healing
of DU.
 The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
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Introduction. Ischaemic digital ulcers (DUs) are a common complica-
tion of SSc.
Methods. This prospective, longitudinal, observational study of
24 months evaluates the impact of recurrent DU on hand disability.
Patients fulfilled ACR or LeRoy–Medsger criteria for SSc, experienced
at least one DU during the previous year with or without active DU at
inclusion, and were eligible for bosentan therapy. Data were collected
on SSc, characteristics of past and present DU, modified Rodnan skin
score, factors influencing hand function and mobility, disability scores
[Cochin hand function scale (CHFS), HAQ disability index (HAQ-DI)]
and quality of life (SF-36).
Results. A total of 217 patients were included between October 2009
and March 2011 in 50 centres. The interim analysis includes 184
patients (128 women). Mean age was 43 (15) years at diagnosis of SSc
and 53 (15) years at inclusion. SSc was diffuse in 44% of patients and
RP started 14 (12) years before inclusion. Of the patients, 11% had
pulmonary arterial hypertension. Mean Rodnan score was 14.3 (8.8).
Time elapsed since the first DU was 6 (7) years. In 47% of patients, DU
was an early complication (first non-RP sign) and 59% had recurrent
DU. Sequelae of DU included loss of substance (62%), autoamputa-
tion (8%) and surgical amputation (10%). Complications were infection
(8%), gangrene (5%) and osteitis (2%). Of the patients, 54% had at
least one active DU at inclusion. In these patients, the mean number of
DU was 2.3 (1.9); 54% had more than one DU, 37% had both hands
involved and on average 2.2 (1.7) fingers were affected. Of the cases,
21% had at least one extended DU (>1 cm). Concomitant mechanical
ulcers were localized at the dorsal face of fingers (19%), bony reliefs
(13%) or calcinosis (1%). DUs were painful [visual analogue scale 6.18
(2.56) vs 2.49 (2.56) without DU] and disabling, involving the dominant
hand in 72% of patients. DU worsened hand disability (median CHFS,
42 with active DU vs 26 without DU, P<0.0001), HAQ-DI and affected
SF-36. Other factors contributing independently to hand disability
were reduced PIP or DIP joint mobility of at least one finger (56 and
66% patients, respectively) and retraction of flexor tendons (45%).
Conclusion. DUs represent an early complication of SSc. They are
painful, affecting often multiple fingers and both hands. In patients with
SSc, DUs are significantly associated with hand disability. Prospective
follow-up at 2 years will allow to further elucidate the specific role that
DU episodes play in the disability of these patients.
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Background. SSc affects multiple organ systems resulting in many
types and degrees of disability. Skin fibrosis, ischaemic pain,
ulceration, arthritis, contracture, myopathy as well as cardiopulmon-
ary, renal and gastrointestinal effects carry significant burden on
emotional, social and physical functioning.
International Classification of Disability, Health and Functioning (ICF) is
a universal framework introduced by the World Health Organization
(WHO) to describe and quantify the impact caused by health
conditions on functioning and disability. ICF uses a standardized
alphanumerical language to describe health states in terms of the bio-
psycho-social model. It is accepted by international health care and
policy-making systems to assess the impact of disease on personal,
scientific, economic and service levels.
Methodology. A comprehensive PubMed search with keywords:
outcome, rehabilitation, function, quality of life, mental, sexual, pain
and disease activity identified five validated measures representing the
broadest range of SSc manifestations (O.D., L.A.S.). Meaningful
concepts were identified in the instruments and linked to the ICF by
 The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
TABLE 1. Questionnaire and ICF codes identified by annotators
Questionnaire No. of
concepts
ICF
code
Description
HAMIS 9 b7101 Mobility of joint functions, mobility
of several joints
b7202 Mobility of bone functions, mobility
of carpal bones
d4400 Fine hand use, picking up
d4401 Fine hand use, grasping
mRSS 17 s8100 Structure of areas of skin, skin of
head and neck region
s8101 Structure of areas of skin, skin of
the shoulder region
s8102 Structure of areas of skin, skin of
upper extremity
s8104 Structure of areas of skin, skin of
lower extremity
s8105 Structure of areas of skin, skin of
trunk and back
RCS 7 b265 Touch function
b2702 Sensory functions related to tem-
perature and other stimuli,
Sensitivity to pressure
b280 Sensation of pain
b810 Protective functions of the skin
b820 Repair functions of the skin
b840 Sensation related to the skin
d430 Lifting and carrying objects
d440 Fine hand use
d445 Hand and arm use
s7302 Structure of hand
NC Duration of attacksa
NC Frequency of attacksa
NC Raynaud’sa
ND Symptomsa
SHAQ VAS 7 b280 Sensation of pain
b430 Lifting and carrying objects
b445 Hand and arm use
b455 Exercise tolerance functions
b4552 Exercise tolerance functions;
fatigability
b5105 Ingestion functions; swallowing
b515 Digestive functions
b525 Defecation functions
b810 Protective functions of the skin
b820 Repair functions of the skin
d440 Fine hand use
HC Digital ulcersa
HC Raynaud’sa
HC Sclerodermaa
ND Activitiesa
SSc GIT 25 b134 Sleep functions
b2801 Sensation of pain, pain in body part
b510 Ingestion functions
b5105 Ingestion functions, swallowing
b5106 Ingestion functions, regurgitation
and vomiting
b515 Digestive functions
b525 Defecation functions
b5250 Defecation functions, elimination of
faeces
b5251 Defecation functions, faecal
consistency
b5252 Defecation functions, frequency of
defecation
b5253 Defecation functions, faecal
continence
b5254 Defecation functions, flatulence
b535 Sensations associated with the
digestive system
b5350 Sensations associated with the
digestive system, sensation of
nausea
b5351 Sensations associated with the
digestive system, feeling bloated
d9250 Recreation and leisure, socializing
PF Feara
aNeed for newly created ICF code.
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two health professionals familiar with ICF linking rules (R.E., L.A.S.).
Agreement was analysed (K.K.).
Results. Nine codes were created to address absence of ICF codes
to describe aspects contained within the instruments. ICF codes
were linked to five validated SSc instruments: 9 ICF codes to Hand
Mobility in Scleroderma Test (HAMIS), 17 to modified Rodnan skin
score (mRSS), 7 to Raynaud’s condition score (RCS), 7 to Scleroderma
Health Assessment Questionnaire (SHAQ) and 25 to SSc
Gastrointestinal Tract Instrument (GIT) (Table 1).
Agreement ranged from 0.8611 (95% CI 0.7500, 0.9444) for HAMIS to
0.9647 (0.9175, 1.000) for mRSS, and from 0.7097 (0.5291, 0.8835) to
0.8964 (0.7631, 1.0000) corrected for chance (Tables 2 and 3). Overall
agreement was 0.9359 (0.9172, 0.9506) and 0.7230 (0.6453, 0.7797)
adjusted for chance. By either measure, agreement between linkers, a
physiotherapist and rheumatologist, was high.
Discussion. This first step, in a methodological series to establish an
ICF language for SSc, was successful in both high agreement of linking
and in exploring potential challenges of linking a complex multi-organ
system disease. Further face, content and construct validation
strategies are now underway. Of the diseases already linked to ICF,
SSc is the most complex thus requiring precise strategies to gain
knowledge from SSc experts including patients, rehabilitation and
nurses. A composite of SSc codes will soon be available for
ICF-engaged health systems. Thus, the global, regional and
personal impact of SSc across cultures, age and socioeconomic
status may be assessed fairly for policy making, provision of services
and funding.
S.11.4 MODIFIABLE PREDICTORS OF FATIGUE IN SSc: A
PROSPECTIVE LONGITUDINAL STUDY OF THE GENISOS
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Objectives. Fatigue has been rated by persons with SSc as their most
bothersome symptom. Longitudinal studies examining the baseline
predictors of fatigue in SSc have not been reported. Our objectives
were to examine the course of fatigue severity over time and to identify
baseline clinical, demographic and psychosocial predictors of
sequentially obtained fatigue scores in early SSc. We also examined
baseline predictors of change in fatigue severity over time.
Methods. We analysed 1090 longitudinal Fatigue Severity Scale (FSS)
scores belonging to 256 patients who were enrolled in the Genetics vs
Environment in Scleroderma Outcomes Study (GENISOS). A
comprehensive list of demographic, objective clinical (including
serology, disease type, Medsger severity scale), patient-reported
clinical and psychosocial variables were examined as potential
predictors of sequentially obtained fatigue levels. Predictive signifi-
cance of baseline variables for sequentially obtained FSS scores was
examined with generalized linear mixed models. Predictors of change
in FSS over time were examined by adding an interaction term
between the baseline variable and time-in-study to the model.
Results. The patients’ mean age was 48.6 years, 47% were
Caucasians and 59% had diffuse cutaneous involvement. The mean
disease duration at enrolment was 2.5 years. The FSS was obtained at
enrolment and follow-up visits (mean follow-up time 3.8 years).
Average baseline FSS score was 4.7 (þ0.96). The FSS was relatively
stable and did not show a consistent trend for change over time
(P¼0.221).
In multivariable model of objective clinical variables, higher Medsger
Gastrointestinal (P¼0.006) and Joint (P¼0.024) Severity Indices, and
anti-U1-RNP antibodies (P¼0.024) were independent predictors of
higher FSS. In the final model, ineffective coping skills captured by
higher Illness Behaviour Questionnaire scores (P<0.001), higher self-
reported pain (P¼ 0.006) and higher Medsger Gastrointestinal Severity
Index (P¼0.009) at enrolment were independent predictors of higher
longitudinal FSS scores.
Baseline DLco per cent predicted was the only independent variable
that significantly predicted a change in FSS scores over time
(P¼0.013), with lower DLCO levels predicting an increase in FSS
over time.
Conclusions. In the first longitudinal fatigue study of persons with
SSc, we identified several modifiable clinical and psychological factors
that predict longitudinal fatigue severity in early SSc. Further
interventional studies are needed to examine whether more effective
management of gastrointestinal, joint and pulmonary manifestations, in
addition to improvement of pain control and coping skills can decrease
perceived fatigue in persons with SSc.
S.11.5 A SELF-ADMINISTERED STRETCHING PROGRAMME
FOR HAND FUNCTION IN SSc: PRELIMINARY RESULTS ON A
1-MONTH FOLLOW-UP OF 13 PATIENTS
V. Riccieri1, I. Sciarra1, L. Maset1, L. Passi1, K. Stefanantoni1,
M. Vasile1, A. Scarno1 and A. Spadaro1
1Department of Internal Medicine and Medical Specialities, University
Sapienza, Rome, Italy.
Hands are greatly involved in most patients with SSc. Besides hand
disability highly influences the activities of daily life, while passive and
active stretching exercises may reduce handicap and help to preserve
function. Thus, we decided to evaluate, using interview-based and
self-administred questionnaires, the functional ability, the health status
and the emotional and physical personal perception of finger joint
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TABLE 2. Point and interval estimates of proportion of agreement with and without correction for chance
Questionnaire No. of concepts No. of ICF codes Proportion of agreement Proportion of agreement corrected for chance
Estimate Lower Limit Upper Limit Estimate Lower Limit Upper Limit
HAMIS 9 4 0.8611 0.7500 0.9444 0.7097 0.5291 0.8835
mRSS 17 5 0.9647 0.9176 1.0000 0.8964 0.7631 1.0000
RCS 7 10 0.9082 0.8367 0.9388 0.6736 0.3879 0.7726
SHAQ 7 11 0.9048 0.8477 0.9524 0.6650 0.4848 0.8279
SSc GIT 25 16 0.9506 0.9318 0.9718 0.6599 0.5306 0.7912
Overall 65 0.9359 0.9172 0.9506 0.7230 0.6453 0.7797
TABLE 3. Linkages from the five pilot instruments according to ICF chapters
Domain Chapter Title Number of categories
generated
Categories shared
amongst instruments
Contributing instruments
Body functions Chapter 1 Mental 3 0 GIT
Chapter 2 Sensory and pain 4 3 GIT, RCS, SHAQ
Chapter 4 Cardiovascular and respiratory 3 0 SHAQ
Chapter 5 Digestive, metabolic and endocrine 12 3 GIT, SHAQ
Chapter 7 Neuromuscular and movement 1 0 HAMIS
Chapter 8 Skin 2 2 RCS, SHAQ
Body structures Chapter 7 Movement 1 1 RCS
Chapter 8 Skin 4 0 mRSS
Activities and participation Chapter 4 Mobility 21 2 GIT, mRSS, RCS, SHAQ
Chapter 5 Self-care 8 0 SHAQ
Chapter 6 Domestic life 3 0 SHAQ
Chapter 7 Interpersonal interactions and relationships 1 0 GIT
Chapter 9 Community, social and civic life 2 0 GIT
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motion in SSc patients before and after 1-month of a self-administred
stretching programme.
Patients and methods. We enrolled 13 consecutive ScS patients, all
females, mean age 62.8 years (mean disease duration 14.2 years)
presenting a clinically evident hand involvement, characterized by
pain and reduced range of motion. All the patients had a detailed
clinical and laboratory assessment and their organ involvement
was also investigated. All patients were evaluated by mental and
physical SF-36, HAQ and with Duruoz Hand Index, at baseline and
1 month after having received instructions on a self-administred
stretching programme. The collected data were compared with
evaluate any possible differences before and after performing this
schedule.
Results. Four (30.8%) patients had a diffuse form of SSc, whereas
9 (69.2%) had a limited form. All of them (100%) were ANA
positive: five (38.5%) had ACAs and five (38.5%) had anti-topo I
antibodies. Six (46%) patients had a modified Rodnan skin score
over 14; digital ulcers were found in 5 (38.5%) cases. At the end of
the 1-month stretching programme, there was a global improve-
ment in the mean values of mental (33.68 vs 41.03) (P<0.008) and
physical (28.92 vs 31.75) SF-36 scores, a reduction in the
mean values of HAQ assessment (1.71 vs 1.38) (P<0.01). Duruoz
Hand Index also improved for those activities requiring
strength (14.84 vs 11.3), skill and accuracy (12.61 vs 10.3) and for
those exercises needing the use of the first three fingers (9.23 vs
8.23).
Conclusion. Although a longer follow-up on a higher number of
patients is needed, our preliminary results show how useful a
stretching programme of the hands can be to improve quality of life
and function in SSc patients.
SESSION 12
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S.12.1 IS H1N1 INFLUENZA VACCINE SAFE AND EFFECTIVE
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Introduction. Immunosuppressed patients are potentially at risk to
suffer from life-threatening pulmonary infections caused by H1N1.
Although pulmonary disease is an important cause of morbidity in
patients with SSc, low rates of influenza vaccination are still observed
in this population due to lack of information and fear of adverse events.
The recent WHO recommendation that the 2010–2011 trivalent
seasonal flu vaccine must contain A/California/7/2009/H1N1-like
virus reinforces the need to access the safety and efficacy of H1N1
vaccination in SSc patients.
Patients and methods. One hundred twenty-seven patients and 234
controls were vaccinated with adjuvant-free influenza A/California/7/
2009 (pH1N1) vaccine. All participants were evaluated pre- and 21
days post-vaccination and serology for anti-H1N1 was performed by
haemagglutination inhibition (HI) assay (HIA). Efficacy was assessed
by seroprotection and seroconversion rates and the factor increase in
geometric mean antibody titre (GMT). Participants received a 21-day
symptom diary card and were instructed to report local and systemic
adverse events. Severe side effects were considered if hospitalization
was required.
Results. SSc patients had mean age of 52 (5.3) years, mean disease
duration of 11.96 (7.9) years and a female predominance (93%).
Of SSc patients, 69.3% had limited cutaneous disease, whereas
30.7% had diffuse cutaneous disease. Half of the patients were on
immunosuppressant therapy (mostly AZA, MTX and CYC). Thirteen
(10%) patients were taking CSs, but only two patients received a daily
dose>10 mg of prednisone. SSc patients and controls presented
similar pre-vaccination GMT (11.2 vs 9.3; P¼0.094) and seroprotec-
tion rates (18.1 vs. 11.5%; P¼ 0.110). After vaccination seroprotection
rates (81.1 vs 82.9%; P¼0.668) and GMT (134.4 vs. 122.9; P¼ 0.654)
rose in both groups. Seroconversion rates (72.4 vs 76.9%; P¼ 0.372)
and factor increase in GMT (12.0 vs 13.2; P¼0.553) were comparable
in both groups. Disease-modifying antirheumatic drugs were not
associated with reduced vaccination responses (P> 0.05). Immuniza-
tion was well tolerated with mild local (7.1 vs 14.1%; P¼0.058) and
minor systemic reactions (23.6 vs 25.6%; P¼0.704) in patients and
controls, respectively. No severe side effect was reported.
Conclusion. Vaccination against H1N1 was safe and induced a
satisfactory response in patients with SSc, including in those under
immunosuppressive therapy. Due to the inherent risks of lower
respiratory infections in this group of patients, physicians should
consider annually influenza vaccination recommendation
(ClinicalTrials.gov, #NCT01151644).
S.12.2 THE AUTOANTIBODY PROFILE OF CHINESE
PATIENTS WITH SSc DIFFERS SIGNIFICANTLY FROM OTHER
ETHNIC GROUPS
J. C. Wang1, S. Assassi2, G. Guo3, W. Z. Tu4, F. K. Tan2,
M. D. Mayes2, J. D. Reveille2, W. Y. Wu5, H. J. Zou5, Y. Q. Zhao3,
H. Y. Chu1, J. Liu1 and X. D. Zhou2
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University, Shanghai, China, 2The University of Texas Medical School
at Houston, Houston, USA, 3Yiling Hospital, Hebei, 4Shanghai
traditional Chinese Medicine-Integrated Hospital, Shanghai and
5Huashan Hospital, Shanghai, China.
Background/Purpose. The presence of autoantibodies to nuclear
and nucleolar proteins is a characteristic feature of SSc. Autoantibody
frequencies may differ in ethnic populations and indicate distinct
clinical outcomes. Our goal was to study SSc-specific autoantibodies
in Chinese patients with SSc, and compare their frequencies with that
in US and Japanese SSc patients.
Methods. Chinese SSc patients (n¼328) were recruited from a
multicentre study including hospitals and outpatient clinics in Shanghai
and Shijiazhuang in China. All patients met the ACR classification
criteria for SSc. Anti-topo antibody (ATA), ACA and anti-RNA
polymerase III (RNAP III) were detected utilizing commercially available
kits. The autoantibody information in Chinese patients was compared
with the serology in the US–Caucasian patients (n¼ 834), recruited
from the GENISOS and Scleroderma Family Registry, as well as
Japanese SSc patients (n¼203) based on published data. Chi-square
test was utilized for the above-mentioned comparisons.
Results. ATA were found in 54.9%, ACA in 10.7% and RNAP III
autoantibodies in only 2.1% of Chinese patients with SSc. This
represents the first report on the frequency of RNAP III in Chinese
patients with SSc. Compared with US patients (ATA in 18.7%, ACA in
32.4% and anti-RNAP III in 17.4%), and to Japanese patients (ATA in
31.5%, ACA in 36.9%, anti-RNAP III in 5.9%), Chinese SSc patients
have a significantly low frequency of RNAP III and ACA, but higher
frequency of ATA (Table 1). The prevalence of diffuse cutaneous
involvement was significantly higher in Chinese patients (62.8%) than
Caucasian (34.8%) and Japanese patients (44.8%) with SSc (Table 1).
Conclusion. The frequencies of SSc-specific autoantibodies differ
significantly in Chinese patients from Caucasians and Japanese
patients with SSc. The higher frequencies of ATA and the lower
occurrence of ACA may indicate a higher risk for developing interstitial
lung disease in Chinese SSc patients, whereas the markedly low
frequency of RNAP III in Chinese SSc patients explains the observed
low prevalence of scleroderma renal crisis in China. Our findings, along
with the previously published data on the association of SSc-specific
antibodies with distinct HLA alleles, suggest that differences in genetic
determinants in various geographic areas may contribute to the
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